about
The Functional Role of PRC2 in Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) - Mechanisms and OpportunitiesCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaSelective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes.DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic LeukemiaMLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemiaTransient potential receptor melastatin-2 (Trpm2) does not influence murine MLL-AF9-driven AML leukemogenesis or in vitro response to chemotherapy.Leukemia stem cells and human acute lymphoblastic leukemia.Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.Epigenetic modifiers in normal and malignant hematopoiesis.Histone profiles in cancer.Eradication of CD19+ leukemia by targeted calicheamicin θ.A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells.A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases.The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors.Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia.Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL-Rearranged Leukemia.HDAC expression patterns in pediatric ALL.Bridging the Gaps: iPSC-Based Models from CHIP to MDS to AML.Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.The role of polycomb repressive complex 2 in early T-cell precursor acute lymphoblastic leukemiaA role for DOT1L inMLL-rearranged leukemiasThe Pediatric Cell Atlas: Defining the Growth Phase of Human Development at Single-Cell ResolutionJMJD6 cleaves MePCE to release positive transcription elongation factor b (P-TEFb) in higher eukaryotes
P50
Q26744506-607719AC-097E-45E5-ACAF-5F5E998647DCQ27025242-2E8C4BB0-601B-44B1-ABDF-4A79166865AEQ33716402-49D8CF1B-CC0F-4CD8-B3BA-33101666BE62Q34313075-297D1E12-FC1F-4D55-BBEE-AE7BB0EA820AQ34918857-3E13D52D-E1D0-48A3-A499-DF76E61A8125Q35329614-9857F9FF-B3D8-42A8-8110-89B071D206C1Q35898171-48688112-4692-44AF-ABE5-DD7B1E6BF820Q36682938-638AA9D2-BD69-4FA7-9C56-2EECDA906577Q36737896-5C49DD44-DC03-4B92-A3B2-7208683B0273Q37022764-5ADAD623-A67C-4C35-BE01-93EBA1740DA7Q37355972-32E3F12C-D297-4157-BC9B-ABFD2E1F8E2CQ37599648-85A66FCF-8DD7-4EBC-B803-FAB73E6532E8Q37633585-E9A4CA3E-D20C-4F36-A4CB-EE408198981EQ38459868-8C14A922-B9BB-4E57-8DBE-4466CFA2ACF9Q38554162-C10452F0-87C4-4C7E-A8D9-D8BB5C662F9CQ39830153-051D6569-7FED-4813-9521-A97DBCB195CDQ40223632-15C3AFDE-0E44-4014-83C3-8D7BFC1800BAQ40565608-F8B6BC31-11DD-4A97-B9B1-9ACBAE9D63C0Q40619723-C8BD5D58-CE85-4570-8B21-FBC8D2B41653Q40665821-456CC899-2087-4E06-9D74-7C24A23C5E8EQ40789665-4E8989D6-CF3F-4C97-9ED3-C2A81B2D1820Q42776339-D7758B44-0DE1-415F-836F-D2AD6E37EF76Q47737893-99A6E863-B097-4A15-ACC1-E9ACD69832FEQ51443595-48AE7396-BB91-44F2-9D10-899A56C730DEQ53675456-1A8B851E-59C3-4ABC-8990-BD4251E4FB40Q62633484-3A9D6F98-FF0E-4CD6-A720-25364C495740Q62633588-BC9F1932-24C2-4E2C-9418-01CD793888B6Q64112163-F19641B0-EB8E-4A05-884B-81843E563367Q89673835-7A5649B2-0331-43A4-8A3F-3B4C24DA00AA
P50
description
researcher
@en
wetenschapper
@nl
name
Kathrin M Bernt
@en
Kathrin M Bernt
@nl
type
label
Kathrin M Bernt
@en
Kathrin M Bernt
@nl
prefLabel
Kathrin M Bernt
@en
Kathrin M Bernt
@nl
P106
P31
P496
0000-0002-0691-356X